OTC Bulletin Board
S & P Company Insight for CRYO-CELL INTL INC |
| |
Profile
|
| |
| Business Summary: Cryo-Cell International, Inc., a private family cord blood stem cell bank, engages in cellular processing and cryogenic cellular storage, with a focus on the collection and preservation of umbilical cord (U-Cord) blood stem cells for family use. | | | Address
700 Brooker Creek Blvd., Suite 1800
Oldsmar
, FL 34677-2905
Phone: 813-749-2100
Fax: 813-855-4745
Website: http://www.cryo-cell.com
| | | Transfer Agent |
|---|
Continental Stock Transfer & Trust Co.
| Employees: 49
ShareHolders: 5300 | Founded: 1989
Domicile: Delaware | | | |
|
|
|
Background
|
| |
| Cryo-Cell International, Inc., a private family cord blood stem cell bank, engages in cellular processing and cryogenic cellular storage, with a focus on the collection and preservation of umbilical cord (U-Cord) blood stem cells for family use. The company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, Lamaze instructors and other childbirth educators, certified nurse-midwives, and other related healthcare professionals. As of November 30, 2009, it stored approximately 200,000 cord blood specimens worldwide for the benefit of newborn babies and other members of their families. Cryo-Cell International also engages in research and development activities to develop technologies related to stem cells other than umbilical cord blood stem cells, such as fetal and maternal stem cells harvested from the placenta. The company discovered a technology related to menstrual stem cells; and launched its C'elle service related to this patent-pending technology in November 2007. This service allows women to store their own menstrual stem cells that may serve as a potential source for various promising regenerative therapies to treat heart disease, diabetes, neurological disorders, Parkinson's and Alzheimer's diseases, and cosmeceutical applications. Cryo-Cell International continues to focus its research and development activities principally on the C'elle service and related new menstrual stem cell technologies. The company was founded in 1989 and is headquartered in Oldsmar, Florida. | | History: INCORPORATED in Delaware Sept. 11, 1989. | | | | | | Capital Expenditures, thousand. US Dollars |
|---|
| Year | Amount | | 2009 | 450 |
| | | | | | Research and Development Expenditures, thousand. US Dollars |
|---|
| Year | Amount | | 2009 | 102 |
| | | | | |
|
|
|
Management
|
| |
Management
|
|---|
| Officers | Position |
|---|
| Mercedes A. Walton | Chairman & Chief Executive Officer | | Jill M. Taymans | Chief Financial Officer | | Dianne Will | Investor Relations Contact |
| | Directors |
|---|
| Michael W. Cho | | Ki Yong Choi | | Scott Christian | | Andrew J. Filipowski | | Anthony P. Finch | | Won Sohn Sung | | Mercedes A. Walton | | | |
|
|
|
Annual Report
|
| |
| Annual Report |
|---|
| | | Income Statement | |
| 2009 | 2008 |
|---|
| REVENUES |
|
| | Revenues | 16,326,684 | 17,278,058 | | EXPENSES |
|
| | Cost of Sales | (4,532,509) | (6,113,514) | | Selling, General and Administrative Expenses | (8,936,679) | (10,827,326) | | Research, Development and Related Engineering Expenses | (102,414) | (194,462) | | Depreciation and Amortization | (385,978) | (408,766) | | Safti-Cell contract cancellation costs | (696,850) | - | | Interest Expense | (1,416,160) | (1,321,771) | | Interest Income | 71,638 | 154,817 | | Equity in (Losses) earnings of Affiliates | (112,769) | (164,337) | | Other-than-temporary Impairment of Marketable Securities | - | (60,736) | | Licensee Income | 1,331,553 | 1,036,965 | | Earnings before Taxes | 1,546,516 | (621,072) | | Income tax | (121,811) | (105,177) | | Net Income (Loss) | 1,424,705 | (726,249) | | SUPPLEMENTARY INFO |
|
| | Operating Income (Loss) | 1,672,254 | (326,746) | | Basic Eps-continuing Operations | 0.12 | (0.06) | | Diluted Eps-continuing Operations | 0.12 | (0.06) |
| | | | Balance Sheet | |
| 2009 | 2008 |
|---|
| ASSETS: |
|
| | CURRENT ASSETS |
|
| | Cash and Cash Equivalents | 6,850,765 | 3,566,366 | | Marketable Securities and Other Investments | 960,000 | 1,125,000 | | Accounts Receivable and Advances | 2,246,181 | 2,250,835 | | Deferred Tax Assets | 15,000 | 21,000 | | Prepaid Expenses and Other Current Assets | 682,215 | 521,041 | | Restricted Cash | 200,000 | 200,000 | | Total Current Assets | 10,954,161 | 7,684,242 | | NON CURRENT ASSETS |
|
| | Property and Equipment | 2,369,888 | 2,570,597 | | Other Investments | 6,404 | 6,404 | | Investment in Saneron Ccel Therapeutics, Inc | 684,000 | 684,000 | | Loans Receivable | 91,758 | 89,411 | | Deposits and Other Assets | 501,917 | 282,122 | | Total Assets | 14,608,128 | 11,316,776 | | LIABILITIES: |
|
| | CURRENT LIABILITIES |
|
| | Accounts Payable | 750,127 | 835,670 | | Accrued Expenses | 2,130,760 | 1,226,045 | | Deferred Revenue | 5,449,483 | 4,939,653 | | Total Current Liabilities | 8,330,370 | 7,001,368 | | NON CURRENT LIABILITIES |
|
| | Deferred Revenue | 7,407,287 | 6,996,264 | | Deferred Tax Liabilities | 15,000 | 21,000 | | Deferred Consulting Obligations | 286,441 | 382,847 | | Long-term Liability-revenue Sharing Agreements | 3,750,000 | 3,750,000 | | SHAREHOLDERS' EQUITY |
|
| | Common Stock-par Value | 117,526 | 117,505 | | Additional Paid in Capital | 24,588,850 | 24,682,328 | | Treasury Stock-common | (484,535) | (807,020) | | Accumulated Deficit | (29,308,756) | (30,733,461) | | Accumulated Other Comprehensive Loss | (94,055) | (94,055) | | Total Shareholders Equity | (5,180,970) | (6,834,703) | | Total Liabilities & Shareholders Equity | 14,608,128 | 11,316,776 |
| | | |
|
|
|
Interim Report
|
| |
| Interim Report
|
|---|
| | | Data Not Available | | | | | | | | | |
|
|
|
Pro Forma Report
|
| |
| Pro Forma Report
|
|---|
| | | Data Not Available | | | | | | | | | |
|
|
|
Quarterly Report
|
| |
| Quarterly Report Information
|
|---|
| | | Quarterly Revenue, US$ |
|---|
| Year | Quarter | Revenue | | 2010 |
1 | 4,240,000 | | 2010 |
2 | 4,300,000 | | 2009 |
1 | 3,860,000 | | 2009 |
2 | 4,240,000 | | 2009 |
3 | 4,210,000 | | 2009 |
4 | 4,010,000 | | 2009 |
Full Year
| 16,330,000 | | 2008 |
1 | 4,170,000 | | 2008 |
2 | 4,520,000 | | 2008 |
3 | 4,460,000 | | 2008 |
4 | 4,130,000 | | 2008 |
Full Year
| 17,280,000 | | 2007 |
1 | 4,170,000 | | 2007 |
2 | 4,450,000 | | 2007 |
3 | 4,550,000 | | 2007 |
4 | 4,290,000 | | 2007 |
Full Year
| 17,460,000 | | 2006 |
1 | 3,690,000 | | 2006 |
2 | 4,480,000 | | 2006 |
3 | 4,590,000 | | 2006 |
4 | 4,420,000 | | 2006 |
Full Year
| 17,180,000 | | 2005 |
1 | 3,270,000 | | 2005 |
2 | 3,570,000 | | 2005 |
3 | 3,770,000 | | 2005 |
4 | 3,840,000 | | 2005 |
Full Year
| 14,450,000 |
| | | | | | Quarterly Net Income, US$ |
|---|
| Year | Quarter | Revenue | | 2010 |
1 | 320,000 | | 2010 |
2 | 350,000 | | 2009 |
1 | 540,000 | | 2009 |
2 | 730,000 | | 2009 |
3 | 430,000 | | 2009 |
4 | (280,000) | | 2009 |
Full Year
| 1,420,000 | | 2008 |
1 | (250,000) | | 2008 |
2 | (360,000) | | 2008 |
3 | (190,000) | | 2008 |
4 | 30,000 | | 2008 |
Full Year
| (760,000) | | 2007 |
1 | (790,000) | | 2007 |
2 | (1,400,000) | | 2007 |
3 | (1,150,000) | | 2007 |
4 | (1,670,000) | | 2007 |
Full Year
| (5,010,000) | | 2006 |
1 | 60,000 | | 2006 |
2 | (860,000) | | 2006 |
3 | (1,080,000) | | 2006 |
4 | 930,000 | | 2006 |
Full Year
| (2,811,400) | | 2005 |
1 | 180,000 | | 2005 |
2 | 120,000 | | 2005 |
3 | 600,000 | | 2005 |
4 | 140,000 | | 2005 |
Full Year
| 1,033,400 |
| | | | | | Quarterly EPS, US$ |
|---|
| Year | Quarter | Revenue | | 2010 |
1 | .03 | | 2010 |
2 | .03 | | 2009 |
1 | .05 | | 2009 |
2 | .06 | | 2009 |
3 | .04 | | 2009 |
4 | (.02) | | 2009 |
Full Year
| .12 | | 2008 |
1 | (.02) | | 2008 |
2 | (.03) | | 2008 |
3 | (.02) | | 2008 |
4 | Nil | | 2008 |
Full Year
| (.06) | | 2007 |
1 | (.07) | | 2007 |
2 | (.12) | | 2007 |
3 | (.10) | | 2007 |
4 | (.14) | | 2007 |
Full Year
| (.43) | | 2006 |
1 | Nil | | 2006 |
2 | (.07) | | 2006 |
3 | (.09) | | 2006 |
4 | .08 | | 2006 |
Full Year
| (.24) | | 2005 |
1 | .01 | | 2005 |
2 | .01 | | 2005 |
3 | .05 | | 2005 |
4 | .01 | | 2005 |
Full Year
| .08 |
| | | |
|
|
|
Stock Data
|
| |
| | | Capitalization as of 11/30/2009: | | | | | Authorized Shares | Outstanding Shares |
|---|
| Preferred $0.01 par | 500,000 | None | | Common $0.01 par | 20,000,000 | 11,752,574so2 |
| | | | LONG TERM DEBT: None. | | | | Common $0.01 par | | | |
Stockholders:
11/30/2009,
5300.
| | PRINCIPAL STOCKHOLDERS: November 30, 2009, Ki Yong Choi owned or controlled 20.9% of the Common, the Portnoy Group 13.6%, and the Filipowski Group 5.5%. | | | |
Transfer Agent: Continental Stock Transfer & Trust Co.
New York
, NY | | | | OTC Bulletin Board( Primary): CCEL | | | | Exchange | Year | High | Low |
|---|
| OTC Bulletin Board | 2009 | 2.5000 | 0.4200 | | OTC Bulletin Board | 2008 | 0.9700 | 0.4000 | | OTC Bulletin Board | 2007 | 3.0000 | 0.7700 | | OTC Bulletin Board | 2006 | 3.8500 | 2.1200 | | OTC Bulletin Board | 2005 | 6.9700 | 2.1000 | | OTC Bulletin Board | 2004 | 4.6000 | 0.5900 | | OTC Bulletin Board | 2003 | 1.7900 | 0.3000 | | NASDAQ Small Cap | 2002 | 6.0000 | 1.4500 | | NASDAQ Small Cap | 2001 | 10.9000 | 2.1200 | | NASDAQ Small Cap | 2000 | 12.5000 | 1.9300 |
|
| | | | DIVIDENDS: Common $0.01 par: No cash.
Stockholders received three Common shares of Stem Cell Preservation Technologies, Inc. for every four Common shares held Aug. 31, 2001. | | | | | |
so2Incl. shares in treas. | |
|
|
|